Research objective is to study processes of lithogenesis at patients with considerably cured urolithiasis at androg-enous therapy. The patients observed in urological clinic of Omsk State Medical Academy have been included. By means of method «case-control» 2 groups have been formed : the basic group - 10 patients with considerably cured urolithiasis and with hypogonadism receiving androgenous therapy and the comparison group - 10 patients with considerably cured urolithiasis and with hypogonadism without receiving androgenous therapy. Processes of lithogenesis at patients who received androgenous therapy have proceeded statistically significantly in comparison with patients without receiving androgenous therapy. It has been proved that there is a negative influence of testosterone deficiency on processes of lithogenesis. The obtained data demonstrate that lithogenic processes at patients with hypogonadism are more expressed and lead to more frequent urolithiasis recurrence. Noninvasiveness, technical simplicity and availability of method «Litos-test» provides its use for express-screening method for inspection of the population and for estimation of antireccurent efficiency of androgen replacement therapy at men with urolithiasis
P.I. Shuster, P.V. Glybochko Condition Of Lithogenesis Processes In Kidneys Secondary To Androgynous Therapies Lithogenesis Processes In Kidneys At Receiving Androgynous Therapy // Saratov Journal of Medical Scientific Research, Vol. 5, Issue 4, 2009, pp. 612-615

Study of age-specific hypogonadism correlation through osteopenia with urolithiasis at men is a new perspective direction uniting endocrinology and somatic urology. Besides comparison groups patients observed in the urological clinic of Omsk State Medical Academy have been included in one-stage continuous research. The method of stratification has allowed distinguishing two groups: group of men with urolithiasis - 140 patients and comparison group - 30 men without urolithiasis. Research methods have included questioning of patients by means of questionnaire AMS and international erectile function index, estimation of body weight index, biochemical indicators of blood serum, general testosterone, ionized calcium, densitometry. Occurrence of hypogonadism at men with urolithiasis has accounted 57,1 % (80 patients), in comparison group (men without urolithiasis) it has accounted 23,3 % (7 patients). Occurrence of decrease in mineral density of bone tissue has been statistically and significantly higher at patients with hypogonadism that proves interrelation of osteo-calcium metabolism disturbances and urolithiasis development. The 1st group has accounted 8,7 % of patients with osteoporosis, the 2nd group - 3,3 %. The 1st group has accounted 70,0% of patients with osteopenia, the 2nd group - 25,0%. Level of testosterone is associated with degree of expressiveness of decrease in mineral density of bone tissue. The lowest indices of testosterone have been at men with osteoporosis. Revealed correlations have shown adverse influence of hypogonadism not only on the sexual status of patient, but also on condition of osteo-calcium metabolism, disturbances of which may cause urolithiasis
P.V. Glybochko, P.I. Shuster Etiopathogenic correlations between age-specific hypogonadism, osteoporosis and urolithiasis at men // Saratov Journal of Medical Scientific Research, Vol. 5, Issue 4, 2009, pp. 604-607

The weakest unit in treatment of urolithiasis is revealing in each specific case etiological factor of lithogenic and carrying out etiotropic therapy, and, hence prevention of urolithiasis relapse. The study of correlation of hypogonadism through osteosinging with urolithiasis at men is the new perspective direction uniting Endocrinology and somatic Urology. In prospective cohort research the patients divided into 2 groups have been included: basic group - patients with considerably cured urolithiasis and hypogonadism, received androgenic therapy (30 persons); comparison group -patients with considerably cured urolithiasis and hypogonadism, not receiving androgen therapy (30 persons). Used: questioning on questionnaire AMS, the International index of erectile functions (IIEF-5), index of weight of a body, haemoglobin, hematocrit, biochemical indicators of blood serum, densitometry, general testosterone, PSA, and ionized calcium. After contra-indications exception (cancer of prostate gland, expressed increase of haemoglobin and hematocrit) the basic group patients were prescribed one of testosterone group drug during the period not less than 6 months: Androgel (Solvay Pharma), Nebido (Bayer Schering Pharma), Sustanon-250 (Organon), Omnadren-250 (Polfa). At the moment of the therapy beginning, patients of both groups were comparable in all investigated indices. Relapse of urolithiasis: against androgenic therapy - 28,6%, in comparison group - 63,2%. The obtained data testify to efficiency of androgenic therapy in respect to prevention of urolithiasis at patients with hypogonadism and confirm the role of hypogonadism as one of etiopathogenetic development factors of urolithiasis. Androgenic therapy was safe. All patients had insignificant increase of general PSA level and statistically significant increase of haemoglobin and hematocrit indicators. However, the received changes did not demand cancellation, or therapy correction.
P.I. Shuster Efficiency and safety of androgenic therapies of hypogonadism at patients with considerably eliminated urolithiasis // Saratov Journal of Medical Scientific Research, Vol. 5, Issue 3, 2009, pp. 327-332